Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159678 | 1.00 | DGAT1 (0.41) | DGAT1CHRM2CHRM3CHRM4PDE4B | |
| SCHEMBL6159675 | 1.00 | DGAT1 (0.41) | DGAT1CHRM2CHRM3CHRM4PDE4B | |
| SCHEMBL1298054 | 0.91 | MAPK1 (0.41) | DGAT1CHRM2CHRM3MAPK1CHRM1 | |
| SCHEMBL3148606 | 0.91 | MAPK1 (0.41) | DGAT1CHRM2CHRM3MAPK1CHRM1 | |
| SCHEMBL8168520 | 0.90 | CHRM2 (0.44) | DGAT1CHRM2CHRM3CHRM4PDE4B | |
| SCHEMBL15057584 | 0.90 | CHRM2 (0.44) | DGAT1CHRM2CHRM3CHRM4PDE4B | |
| SCHEMBL18745507 | 0.90 | DGAT1 (0.38) | DGAT1CHRM2CHRM3CHRM4PDE4B | |
| SCHEMBL14347087 | 0.90 | CHRM2 (0.44) | DGAT1CHRM2CHRM3CHRM4PDE4B | |
| SCHEMBL8150145 | 0.90 | CHRM2 (0.44) | DGAT1CHRM2CHRM3CHRM4PDE4B | |
| SCHEMBL8175311 | 0.90 | CHRM2 (0.44) | DGAT1CHRM2CHRM3CHRM4PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949662-B2 | Cis-substituted aminocyclopropane derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-0919553-B1 | cis-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20020183523-A1 | Cis-substituted aminocyclopropane derivative | DAIICHI PHARMACEUTICAL CO., LTD | 2002-12-05 | — | — | US | disclosed |
| US-6462040-B1 | MICROBIOCIDES; BACTERIOCIDES; ANTIPROTOZOA AGENTS; QUINOLONE ANTIBIOTICS; SIDE EFFECT REDUCTION; ANTIBIOTIC-RESISTANT BACTERIA INCLUDING STAPHYLOCCOCUS; VETERINARY MEDICINE | DAIICHO PHARMACEUTICAL CO., LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| US-6391889-B2 | POTENT ANTIMICROBIAL ACTIVITY ON BROAD RANGE OF MICROORGANISMS, E.G., STAPHYLOCOCCUS, GRAMPOSITIVE BACTERIA AND QUINOLONE ANTIBIOTIC RESISTANCE; SIDE EFFECT REDUCTION; NONTOXIC | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| US-20020052502-A1 | Cis-substituted aminocyclopropane derivative | DAIICHI PHARMACEUTICAL CO., LTD. | 2002-05-02 | — | — | US | disclosed |
| US-20020002182-A1 | CIS-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| EP-0919553-A1 | cis-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052502-A1 | Cis-substituted aminocyclopropane derivative | SLC11A2, MYD88, ARG1 | DGAT1 1326/4885CHRM2 4587/4885CHRM3 4549/4885 |
| US-20020002182-A1 | CIS-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | PHOSPHO1, CCR2, ECH1 | DGAT1 271/4885CHRM2 290/4885CHRM3 235/4885 |
| US-20020183523-A1 | Cis-substituted aminocyclopropane derivative | SLC11A2, MYD88, ARG1 | DGAT1 1326/4885CHRM2 4587/4885CHRM3 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.